Black Diamond Therapeutics (BDTX) Total Current Liabilities (2018 - 2026)

Black Diamond Therapeutics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $14.5 million for Q1 2026.

• Quarterly Total Current Liabilities fell 13.73% year-over-year to $14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.5 million (down 13.73% YoY) and the FY2025 annual result came in at $15.7 million, down 23.54% from the prior year.
• Total Current Liabilities was $14.5 million for Q1 2026 at Black Diamond Therapeutics, down from $15.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $21.1 million in Q3 2022 and bottomed at $12.8 million in Q1 2023.
• A 5-year average of $17.2 million and a median of $16.8 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities sank 35.45% — and 2024, when it surged 38.06%.
• Black Diamond Therapeutics' Total Current Liabilities stood at $15.3 million in 2022, then rose by 28.73% to $19.6 million in 2023, then increased by 4.72% to $20.6 million in 2024, then decreased by 23.54% to $15.7 million in 2025, then dropped by 7.61% to $14.5 million in 2026.
• Business Quant data shows BDTX's Total Current Liabilities at $14.5 million in Q1 2026, $15.7 million in Q4 2025, and $15.5 million in Q3 2025.